Avenue Therapeutics Stock Return On Equity
| ATXI Stock | USD 0.38 0.02 5.56% |
Avenue Therapeutics fundamentals help investors to digest information that contributes to Avenue Therapeutics' financial success or failures. It also enables traders to predict the movement of Avenue Pink Sheet. The fundamental analysis module provides a way to measure Avenue Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avenue Therapeutics pink sheet.
Avenue |
Avenue Therapeutics Company Return On Equity Analysis
Avenue Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Avenue Therapeutics Return On Equity | -5.35 |
Most of Avenue Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avenue Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Avenue Therapeutics has a Return On Equity of -5.351. This is 77.68% lower than that of the Pharmaceuticals sector and 85.32% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Avenue Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avenue Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Avenue Therapeutics could also be used in its relative valuation, which is a method of valuing Avenue Therapeutics by comparing valuation metrics of similar companies.Avenue Therapeutics is currently under evaluation in return on equity category among its peers.
Avenue Fundamentals
| Return On Equity | -5.35 | ||||
| Return On Asset | -4.72 | ||||
| Current Valuation | (1.73 M) | ||||
| Shares Outstanding | 2.05 M | ||||
| Shares Owned By Insiders | 25.23 % | ||||
| Shares Owned By Institutions | 15.32 % | ||||
| Number Of Shares Shorted | 92.16 K | ||||
| Price To Earning | (10.52) X | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | 4.05 M | ||||
| Net Income | (10.38 M) | ||||
| Cash And Equivalents | 890 K | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 1.2 M | ||||
| Debt To Equity | 23.40 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 1.63 X | ||||
| Cash Flow From Operations | (9.45 M) | ||||
| Short Ratio | 0.65 X | ||||
| Earnings Per Share | 24.78 X | ||||
| Target Price | 8.0 | ||||
| Beta | -0.29 | ||||
| Market Capitalization | 862.65 K | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (90.93 M) | ||||
| Working Capital | 654 K | ||||
| Current Asset | 111.05 K | ||||
| Current Liabilities | 4.67 M | ||||
| Net Asset | 1.85 M |
About Avenue Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avenue Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avenue Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avenue Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Avenue Pink Sheet
Avenue Therapeutics financial ratios help investors to determine whether Avenue Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avenue with respect to the benefits of owning Avenue Therapeutics security.